First Quadrant’s Theravance Biopharma TBPH Stock Holding History

First Quadrant’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,867	Closed	-$81K	–	712
2020 Q2	$81K	Buy	+3,867	New	+$99.3K	0.01%	597

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

First Quadrant's TBPH Position: Q3 2020 in Review

First Quadrant sold out of Theravance Biopharma (TBPH) in Q3 2020, closing a stake of 3,867 shares — an estimated $81K sold.

First Quadrant first reported a position in TBPH in Q2 2020 and held it in 1 quarter. The position peaked at $81K in Q2 2020. 118 funds tracked by Wall St. Rank hold TBPH as of Q3 2020.

First Quadrant reported no remaining Theravance Biopharma position as of Q3 2020 after selling out during the quarter.
First Quadrant sold 3,867 Theravance Biopharma shares in Q3 2020, an estimated $81K.
First Quadrant first reported a position in Theravance Biopharma in Q2 2020 and held it in 1 quarter.
First Quadrant's Theravance Biopharma position peaked at $81K in Q2 2020.
118 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2020.

Based on First Quadrant's 13F filing for Q3 2020, filed 28 Oct 2020.